Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.
- Associated Conditions
- Type 2 Diabetes Mellitus
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 465
- Registration Number
- NCT04564872
- Locations
- 🇨🇳
Inner Mongolia Baogang Hospital, Baotou, Inner Mongolia, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Hospital Regional de Alta Especialidad del Bajio
- Target Recruit Count
- 70
- Registration Number
- NCT04542213
- Locations
- 🇲🇽
Hospital Regional de Alta Especialidad del Bajìo, Leòn, Guanajuato, Mexico
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
- Conditions
- Metabolic DiseaseEndocrine System DiseasesCOVID 19CoronavirusDiabetes Mellitus, Type 2Diabetes MellitusDipeptidyl-Peptidase IV InhibitorsLinagliptinSevere Acute Respiratory Syndrome Coronavirus 2Sars-CoV2
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT04371978
- Locations
- 🇮🇱
Shamir Medical Center, Be'er Ya'aqov, Israel
🇮🇱Rabin Medical Center, Hasharon Campus, Petah tikva, Israel
🇮🇱Rabin Medical Center, Beilinson Campus, Petah tikva, Israel
Effects of DPP4 Inhibition on COVID-19
- Conditions
- Coronavirus InfectionType 2 Diabetes
- Interventions
- Drug: Insulin regimen
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- University of Miami
- Registration Number
- NCT04341935
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT04180813
- Locations
- 🇨🇳
Huai'an first people's hospital, Huai'an, China
🇨🇳Dongying People's Hospital, Dongying, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, China
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
- Conditions
- Impaired Glucose TolerancePrediabetic StateInsulin Resistance
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Universidad de Guanajuato
- Target Recruit Count
- 31
- Registration Number
- NCT04088461
- Locations
- 🇲🇽
Universidad de Guanajuato, León, Guanajuato, Mexico
Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TQ-F3083 capsule 10 mgDrug: TQ-F3083 capsule 20 mgDrug: TQ-F3083 blank analog capsule
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03986073
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
Linagliptin in Post-renal Transplantation
- Conditions
- Transplanted Kidney Complication
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Universidad de Guanajuato
- Target Recruit Count
- 28
- Registration Number
- NCT03970668
Replication of the CARMELINA Diabetes Trial in Healthcare Claims
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 101830
- Registration Number
- NCT03936036
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.
- Conditions
- Type2 Diabetes Mellitus
- Interventions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.